v3.24.3

Condensed Consolidated Balance Sheet (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 37,080	$ 21,481
Prepaid expenses	65,414	108,368
Other Current Assets
Total Current Assets	102,494	129,849
Equipment, net	1,325	4,048
TOTAL ASSETS	103,819	133,897
Current Liabilities
Accounts payable	790,241	578,378
Related party payable	2,285,562	1,454,986
Accrued expenses	164,053	156,434
Note Payable	57,597	55,679
Total Current Liabilities	3,297,453	2,245,477
TOTAL LIABILITIES	3,297,453	2,245,477
Stockholders’ Equity
Preferred stock $.001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock $.001 par value; 150,000,000 shares authorized; 11,346,535 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	11,346	11,346
Additional paid-in capital	4,449,966	4,399,019
Accumulated deficit	(7,654,946)	(6,521,945)
TOTAL STOCKHOLDERS’ EQUITY	(3,193,634)	(2,111,580)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 103,819	$ 133,897

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Accustem Sciences Inc. 10-Q